HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $12 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Ocular Therapeutix (NASDAQ:OCUL) and maintained a $12 price target.

August 08, 2023 | 4:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ocular Therapeutix's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $12 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and a maintained price target by a reputable firm like HC Wainwright & Co. is likely to boost investor confidence in Ocular Therapeutix, potentially leading to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100